Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1

136Citations
Citations of this article
104Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Functional pancreatic neuroendocrine tumours (PNETs) are mainly represented by insulinoma, which secrete insulin independent of glucose and cause hypoglycaemia. The major genetic alterations in sporadic insulinomas are still unknown. Here we identify recurrent somatic T372R mutations in YY1 by whole exome sequencing of 10 sporadic insulinomas. Further screening in 103 additional insulinomas reveals this hotspot mutation in 30% (34/113) of all tumours. T372R mutation alters the expression of YY1 target genes in insulinomas. Clinically, the T372R mutation is associated with the later onset of tumours. Genotyping of YY1, a target of mTOR inhibitors, may contribute to medical treatment of insulinomas. Our findings highlight the importance of YY1 in pancreatic β-cells and may provide therapeutic targets for PNETs. © 2013 Macmillan Publishers Limited.

Cite

CITATION STYLE

APA

Cao, Y., Gao, Z., Li, L., Jiang, X., Shan, A., Cai, J., … Ning, G. (2013). Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1. Nature Communications, 4. https://doi.org/10.1038/ncomms3810

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free